Selective BRD4 Degrader Molecules for Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current selective degraders for BET proteins, particularly BRD4, face challenges with dose-limiting toxicities and lack of high selectivity, as well as residual bromodomain inhibition leading to undesired toxicity, due to their reliance on pan-BET ligands and non-specific targeting.
Innovation Solution
Development of a highly selective BRD4-BD1 inhibitor, iBRD4-BD1, which selectively degrades BRD4 through engagement of its N-terminal bromodomain, offering 23-6000-fold selectivity over other BET bromodomains, and is used to design proteolytic targeting chimeric molecules for targeted protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pan-BET inhibitors are used to target all eight BET bromodomains, then therapeutic efficacy is improved, but dose-limiting toxicities increase significantly
Solution Approach 1:
The patent segments the pan-BET inhibition approach into selective single-domain inhibition. Instead of targeting all eight BET bromodomains simultaneously with pan-BET inhibitors, the invention develops inhibitors that selectively target a single bromodomain (BD1 or BD2) of BRD4. This segmentation allows therapeutic efficacy to be maintained through specific target engagement while reducing off-target effects on other BET family members, thereby lowering dose-limiting toxicities.
Solution Approach 2:
The patent applies local quality by creating inhibitors with highly selective binding properties for specific bromodomain subtypes. The selective inhibitors exhibit 23-6000-fold selectivity for their target bromodomain over other BET bromodomains, enabling localized therapeutic action at the molecular level. This selective local engagement preserves beneficial therapeutic effects while minimizing harmful systemic effects associated with pan-BET inhibition.
2Object-affected harmful factors
If selective inhibitors targeting single BET bromodomains are developed, then dose-limiting toxicities are reduced, but selectivity remains a significant challenge due to high homology
Solution Approach 1:
The patent employs parameter changes by optimizing the chemical structure of inhibitors to achieve differential binding affinity across highly homologous bromodomains. Through systematic modification of molecular parameters (functional groups, stereochemistry, linker properties), the invention achieves 23-6000-fold selectivity for the target bromodomain. This allows selective inhibition to be achieved despite the high sequence homology among BET bromodomains, resolving the selectivity challenge while maintaining reduced toxicity.
3Reliability
If targeted protein degradation is used instead of inhibition, then therapeutic efficacy is improved, but dose-limiting toxicities including thrombocytopenia occur due to compensatory roles of BRD2 and BRD3
Solution Approach 1:
The patent applies segmentation by designing degraders that selectively target a single bromodomain of BRD4 rather than all BET proteins. This selective single-domain targeting ensures that BRD2 and BRD3, which play compensatory roles in thrombopoiesis, are not degraded. The segmented approach maintains therapeutic efficacy through specific BRD4 degradation while preserving essential functions of other BET family members, thereby preventing thrombocytopenia.
Solution Approach 2:
The patent uses local quality by implementing highly selective degradation of specific BRD4 domains. The degraders exhibit localized action at the molecular level, degrading only the targeted bromodomain-containing BRD4 protein while leaving other BET family proteins intact. This selective local degradation maintains therapeutic benefits while avoiding the pleiotropic effects and thrombocytopenia associated with pan-BET degradation.
4Reliability
If pan-BET degraders are used to degrade BET-family proteins, then therapeutic efficacy is improved, but pleiotropic effects confound interpretation of individual BET-protein roles
Solution Approach 1:
The patent applies segmentation by developing degraders that selectively target individual bromodomains of BRD4 rather than all BET proteins. This segmented approach enables researchers to study the specific functional contribution of targeted BRD4 domains in disease models without the confounding pleiotropic effects of pan-BET degradation. The selective degradation provides clean, interpretable data about individual protein roles while maintaining therapeutic efficacy.
Data Source
AI summary
The invention provides a compound of formula (I):or a salt thereof wherein B, L, and X have any of the values defined in the specification, as well as compositions comprising a compound of formula (I) or a salt thereof. The compounds selectively degrade BRD4, and are useful as to treat cancer and inflammatory conditions.